The Hindu Business Line : Cancer drug: Nicholas to file for approvals

NICHOLAS Piramal India Ltd (NPIL) is set to file for regulatory approvals for its cancer drug that could be applicable in lukaemia, breast or prostrate cancer.

NPIL's Chief Scientific Officer, Dr Swati Piramal, told this to newspersons on Monday at the sidelines of the India Economic Summit 2003, organised by the World Economic Forum and CII.

She said that phase I clinical trials were slated for June 2004, though the company was undecided about whether it would do its phase I trials in India or abroad.

"We would prefer to do the trials in India, but the approval time of about nine months is too long."

Article E-Mail :: Comment :: Syndication

Stories in this Section
IDL blast leaves 7 workers dead

Nestle has no plan to delist, says Donati

Grand hotel group scouting for property in London

Tata postpones Indigo Station Wagon, Indica Sport launches

Indraprastha Gas wants Maruti to make CNG-run cars

Cancer drug: Nicholas to file for approvals

A.T.Kearney to change logo, governance system

Jain Irrigation pref allotment

Open offer for 36.42 pc of SRF Polymers

McDowell, Empee locked in trademark row

ECB curbs — A clichéd approach to tackling forex riches?

IVRCL net rises

Micro Group to merge 4 cos

Sanmar Properties to merge with Chemplast

`Corporates must create trustworthiness'

Steelage Industries plans expansion